Brokerages expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will post ($1.21) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Xeris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.24) and the highest estimate coming in at ($1.17). Xeris Pharmaceuticals reported earnings of ($0.98) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 23.5%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, March 4th.
According to Zacks, analysts expect that Xeris Pharmaceuticals will report full year earnings of ($4.79) per share for the current fiscal year, with EPS estimates ranging from ($4.84) to ($4.73). For the next fiscal year, analysts forecast that the business will post earnings of ($3.37) per share, with EPS estimates ranging from ($3.68) to ($3.06). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.22) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.01. Xeris Pharmaceuticals had a negative net margin of 6,697.33% and a negative return on equity of 150.08%. The firm had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.20 million.
Several equities research analysts have commented on XERS shares. Mizuho reissued a “buy” rating and set a $22.00 price target on shares of Xeris Pharmaceuticals in a research report on Thursday, November 21st. ValuEngine cut shares of Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, September 30th. Royal Bank of Canada set a $18.00 price target on shares of Xeris Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Zacks Investment Research raised shares of Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 16th.
NASDAQ:XERS traded up $0.14 on Wednesday, hitting $8.94. 125,806 shares of the company’s stock were exchanged, compared to its average volume of 196,196. The firm has a 50-day moving average price of $8.34 and a 200-day moving average price of $10.21. The company has a debt-to-equity ratio of 1.33, a current ratio of 5.96 and a quick ratio of 5.96. Xeris Pharmaceuticals has a 52 week low of $6.85 and a 52 week high of $20.90. The company has a market cap of $241.07 million, a P/E ratio of -1.79 and a beta of -0.39.
In other news, insider Paul R. Edick bought 17,935 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were bought at an average cost of $8.55 per share, with a total value of $153,344.25. Following the acquisition, the insider now owns 172,935 shares in the company, valued at $1,478,594.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Steven Prestrelski sold 27,700 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $9.00, for a total transaction of $249,300.00. 7.43% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. IHT Wealth Management LLC raised its holdings in shares of Xeris Pharmaceuticals by 141.8% in the 2nd quarter. IHT Wealth Management LLC now owns 40,914 shares of the company’s stock valued at $468,000 after purchasing an additional 23,994 shares during the period. BlackRock Inc. raised its holdings in shares of Xeris Pharmaceuticals by 19.5% in the 2nd quarter. BlackRock Inc. now owns 2,138,781 shares of the company’s stock valued at $24,468,000 after purchasing an additional 348,308 shares during the period. Vanguard Group Inc. raised its holdings in shares of Xeris Pharmaceuticals by 7.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,219,153 shares of the company’s stock valued at $13,947,000 after purchasing an additional 81,209 shares during the period. Wells Fargo & Company MN raised its holdings in Xeris Pharmaceuticals by 241.5% in the 2nd quarter. Wells Fargo & Company MN now owns 41,973 shares of the company’s stock valued at $480,000 after acquiring an additional 29,682 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in Xeris Pharmaceuticals by 2.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 54,773 shares of the company’s stock valued at $627,000 after acquiring an additional 1,434 shares during the period. 66.37% of the stock is currently owned by institutional investors.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Recommended Story: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.